Epoprostenol Sodium (Epoprostenol Sodium) Patent Expiration, LOE Window & CMS Spending

Epoprostenol Sodium (Epoprostenol Sodium) by Sun Pharmaceutical: Multi-Source Generic Molecule, 0 AB generics, $729K 2024 CMS Part D & Medicaid spend, and $45 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSun Pharmaceutical
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$729K
2024 Medicare Part D Spend$38K
2024 Medicaid Spend$691K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($45 intro WAC)